• Coronavirus, Novartis and Curevac together for the anticovid vaccine

  • Covid, Ema initiates CureVac vaccine examination

  • Vaccine, Von der Leyen: tomorrow contract with CureVac for 405 million doses

  • Berlin, the state enters the biotech group CureVac with a share of 300 million

Share

01 July 2021 The vaccine against Covid-19 developed by the German laboratories CureVac has an efficacy rate of 48% to prevent the disease, well below that of the other messenger RNA vaccines developed so far. The same company that makes the vaccine said it after conducting large-scale clinical trials.



Test data from CureVac, the cheapest and easiest-to-store mRNA preparation hoped to be distributed worldwide, did not deliver the desired results. 



According to CureVac, the German pharmaceutical company that produced the vaccine, it could in part depend on the coronavirus variants widespread in the ten countries between Europe and Latin America where the phase 3 studies took place.



Among the test participants, "the CVnCoV vaccine candidate showed an overall efficacy of 48% (83 cases in the vaccinated group, versus 145 in the placebo group) against Covid-19 disease, regardless of severity," he said in a statement. CureVac, which has signed an important vaccine order with the European Union.



The study, the website states, was "conducted in 10 countries in an environment of rapidly evolving variants; 15 Covid-19 variant strains present for efficacy analysis; the original strain almost completely absent". , "significant protection among participants in the age group between 18 and 60 years, with an efficacy of 53% (vaccine 71 vs.136 placebo) against diseases of any severity and on all 15 identified strains; the protection against moderate to severe disease was calculated as 77% (9 vaccine vs 36 placebo). In the same age group, CVnCoV provided 100% protection (vaccine 0 vs 6 placebo) against hospitalization or death .



In participants over the age of 60, which represented 9% of the cases analyzed, the available data did not allow a statistically significant determination of efficacy. The data confirm the favorable safety profile of CVnCoV in all age groups. The study will continue to complete follow-up analyzes for study participants. The available data were communicated to the European Medicines Agency (EMA) ".